“Our team of 20 scientist and engineers have been developing our next-generation molecular detection since 2016 and have built an expansive patent portfolio,” said Dr Dalton. Kernel was an early stage investor in the business, putting €650,000 into the venture back in its initial funding round in 2014 alongside Enterprise Ireland.Īltratech was founded by semiconductor specialist Tim Cummins, biotechnologist Brian Farrell and chief executive Dr Tara Dalton. Enterprise Ireland has invested €500,000 and Claret Capital is providing a €1.5 million venture debt facility. The latest funds have come from Bank of Ireland’s Kernel Capital Growth Fund and Infinity Capital, which have both invested €1.5 million. Clare company Altratech has raised €5 million, which it said would be used to further develop its “next generation molecular detection” programme.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |